Cancer

Acinic cell carcinoma

Immunohistochemistry

Internal medicine

Myoepithelial cell

Oncology

Medicine

Salivary gland

Mucoepidermoid carcinoma

Adenoid cystic carcinoma

Salivary duct carcinoma

Pleomorphic adenoma

Carcinoma

Adenocarcinoma

Pathology

Frontiers in Oncology

HER2 aberrations in salivary gland carcinomas (SGC) as well as benefit of HER2 directed therapy have been reported in small studies. However, reliable estimates of the prevalence of HER2 positivity in SGC and its various histological subtypes are lacking.To assess the prevalence of HER2 positivity in histological subtypes of salivary gland carcinomas (SGC).Studies were identified by a systematic review of the literature. Data on in situ hybridization (ISH) and immunohistochemistry (IHC) were extracted to derive pooled prevalence estimates calculated by a random effects model. Characteristics of the studies were extracted for subgroup analysis.Fifty studies including 3372 patients were identified, providing data on sixteen histological subtypes. Based on the meta-analysis, the estimated prevalence of HER2 positivity were 43% (95% CI: 36% - 51%) in salivary duct carcinoma (SDC), 39% (95% CI: 32% - 45%) in carcinoma ex pleomorphic adenoma (CEP), 17% (95% CI: 7.5% - 33%) in squamous cell carcinoma (SCC), 13% (95%...

HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis